{"id":"W2803642760","doi":"10.1016/j.jtho.2018.05.015","title":"Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; McMaster University; Juravinski Cancer Centre","funders":"Gilead Sciences; Amgen; Pfizer; Samsung; Genentech; Celgene; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Erlotinib; Nivolumab; Oncology; Mutant; Internal medicine; Epidermal growth factor receptor; Cancer; Immunotherapy; Genetics; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004892471,0.0001290159,0.0005174426,0.0002408924,0.00004266645,0.00000767462,0.0001308347,0.0001280612,0.0002561894],"category_scores_gemma":[0.00007136021,0.00008737395,0.00009905524,0.0002968398,0.0001954073,0.0001321906,0.0000213679,0.0003282153,0.00001350747],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008108007,"about_ca_system_score_gemma":0.000711141,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001752875,"about_ca_topic_score_gemma":0.0001158157,"domain_scores_codex":[0.9986471,0.0001000257,0.0005670721,0.0001379872,0.0002935817,0.0002542634],"domain_scores_gemma":[0.9987393,0.00006306941,0.0005325525,0.0001703451,0.0003849925,0.0001097547],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2095379,0.0009954243,0.05990394,0.00005165621,0.0002857371,0.0003450451,0.001102199,0.000006278004,0.005787284,0.000006274326,0.001445715,0.7205325],"study_design_scores_gemma":[0.03728304,0.05255484,0.7740978,0.001059307,0.0002871585,0.001007013,0.000882486,0.00004416706,0.005776106,0.00007706073,0.1266061,0.0003249341],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940422,0.0002931594,0.00009903921,0.00177053,0.0007904622,0.0002884203,0.000002674269,0.000008943711,0.002704638],"genre_scores_gemma":[0.9954277,0.00005350369,0.002955351,0.0009213552,0.000335178,0.000003197179,0.000002197318,0.00001933657,0.0002821891],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7202076,"threshold_uncertainty_score":0.3563006,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01299852903325221,"score_gpt":0.3669118231277166,"score_spread":0.3539132940944644,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}